First Manhattan’s Puma Biotechnology PBYI Stock Holding History

First Manhattan’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-425,900	Closed	-$16.5M	–	1424
2019 Q1	$16.5M	Sell	425,900 -10,300	-2%	-$315K	0.1%	119
2018 Q4	$8.88M	Buy	+436,200	New	+$13.1M	0.06%	173

Other funds holding PBYI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

First Manhattan's PBYI Position: Q2 2019 in Review

First Manhattan sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 425,900 shares — an estimated $16.5M sold.

First Manhattan first reported a position in PBYI in Q4 2018 and held it in 2 quarters. The position peaked at $16.5M in Q1 2019. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

First Manhattan reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
First Manhattan sold 425,900 Puma Biotechnology shares in Q2 2019, an estimated $16.5M.
First Manhattan first reported a position in Puma Biotechnology in Q4 2018 and held it in 2 quarters.
First Manhattan's Puma Biotechnology position peaked at $16.5M in Q1 2019.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on First Manhattan's 13F filing for Q2 2019, filed 16 Aug 2019.